These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 352663)
1. Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Heel RC; Brogden RN; Speight TM; Avery GS Drugs; 1978 Jul; 16(1):1-24. PubMed ID: 352663 [TBL] [Abstract][Full Text] [Related]
2. Tamoxifen in postmenopausal women a safety perspective. Robinson E; Kimmick GG; Muss HB Drugs Aging; 1996 May; 8(5):329-37. PubMed ID: 8935395 [TBL] [Abstract][Full Text] [Related]
3. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost. Mäenpää JU; Ala-Fossi SL Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556 [TBL] [Abstract][Full Text] [Related]
4. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. McKeage K; Curran MP; Plosker GL Drugs; 2004; 64(6):633-48. PubMed ID: 15018596 [TBL] [Abstract][Full Text] [Related]
6. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer. Dunn C; Keam SJ Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574 [TBL] [Abstract][Full Text] [Related]
7. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer]. Novoa Vargas A; Font López KC; Amador DD Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856 [TBL] [Abstract][Full Text] [Related]
8. Pure oestrogen antagonists for the treatment of advanced breast cancer. Howell A Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425 [TBL] [Abstract][Full Text] [Related]
9. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Wiseman LR; Goa KL Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526 [TBL] [Abstract][Full Text] [Related]
10. Letrozole: a review of its use in postmenopausal women with breast cancer. Simpson D; Curran MP; Perry CM Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G; Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. Mouridsen H; Chaudri-Ross HA Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634 [TBL] [Abstract][Full Text] [Related]
13. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]. de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633 [TBL] [Abstract][Full Text] [Related]
14. Effects of tamoxifen in relation to breast cancer. Jordan VC Br Med J; 1977 Jun; 1(6075):1534-5. PubMed ID: 871651 [TBL] [Abstract][Full Text] [Related]
15. New vs old fashioned oestradiol antagonists in mammary carcinoma: 'in vitro' and 'in vivo' pharmacological approaches. de Cupis A; Schettini G; Favoni RE Pharmacol Res; 1999 May; 39(5):335-44. PubMed ID: 10328990 [TBL] [Abstract][Full Text] [Related]
16. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N; Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193 [TBL] [Abstract][Full Text] [Related]
17. Management of breast cancer. Cohen IA; Keller JH; Abate MA Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963 [TBL] [Abstract][Full Text] [Related]
18. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. Tobias JS Int J Biochem Cell Biol; 2004 Nov; 36(11):2112-9. PubMed ID: 15313457 [TBL] [Abstract][Full Text] [Related]
19. The curability of breast cancer and the treatment of advanced disease. Guarneri V; Conte PF Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]